Impact Analysis of Covid-19
The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market – Market Insights
Poly ADP-Ribose Polymerase (PARP) inhibitors are long chain containing 17 enzymes that combine several (poly) units of ADP-ribose in a chain and transfer them to the target proteins. This helps to restore DNA when it is damaged by many factors such as exposure to UV radiation, some anti-cancer drugs and others. PARP inhibitors block an enzyme critical to the repair of single stranded breaks in the DNA. Inhibition of this DNA repair enzyme can lead to cell death, particularly in cancer cells that carry deficiency of other DNA repair pathways.
Furthermore, PARP inhibitors play an effective maintenance role in current cancer treatments owing to their therapeutic effect on ovarian cancer. According to the World Ovarian Cancer Coalition statistics of 2018, there are around 600,000 women diagnosed with an ovarian cancer for a period of 5 years.
The global PARP (Poly ADP-Ribose Polymerase) inhibitor market was valued at US$ 887.7 Mn in 2018, and is expected to exhibit a CAGR of 32.4% over the forecast period (2019–2027).
Figure 1. Global PARP Inhibitor Market Value (US$ Mn), by Region, 2018
Source: Coherent Market Insights Analysis (2019)
Increasing research and development activities by market players are expected to increase application of PARP inhibitors
Currently, PARP is indicated for treatment of ovarian cancer and breast cancer. However, researchers are focused on expanding the application of PARP inhibitors. For instance, in December 2018, University of Michigan Rogel Cancer Center planned Phase II trials of the investigational drug combination of olaparib and AZD6738 for treatment of metastatic castration-resistant prostate cancer.
In May 2019, Clovis Oncology, Inc., in collaboration with Bristol-Myers Squibb Company and Foundation Medicine Inc., initiated Phase II studies to evaluate rucaparib in combination with nivolumab in patients with high-grade serous or endometrial ovarian cancer. The study is expected to be completed in January 2022.
In April 2019, Pfizer, Inc., received positive feedback from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for TALZENNA (talazoparib), an oral poly (ADP-ribose) polymerase (PARP) inhibitor indicated for treatment in locally advanced (LA) or metastatic breast cancer (MBC).
Moreover, delays in regulatory approvals can result in delayed marketing of the product, which can affect the revenue of the manufacturer. Similarly, delay in post approval of the drug for other therapeutic indications results in increasing clinical trials costs and can impact the labelling and approval status of currently marketed products. Thus, these factors are expected to hamper the PARP inhibitor market growth.
Figure 2. Global PARP Inhibitor Market Share (%), by Application
Source: Coherent Market Insights Analysis (2019)
Increasing approvals of innovative drugs molecules in PARP inhibitor market
In the recent past, several key players in the market have received approvals for their PARP inhibitor molecules which is expected to create a lucrative environment for growth of global PARP inhibitors market in the near future.
In January 2018, AstraZeneca PLC received approval from the Japanese Ministry of Health, Labour and Welfare for Lynparza (olaparib) tablets indicated as maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer. Lynparza is the first approved poly ADP-ribose polymerase (PARP) inhibitor in Japan.
In October 2018, Pfizer, Inc., received the U.S. Food and Drug Administration approval for TALZENNA (talazoparib), a (PARP) inhibitor indicated for treatment in locally advanced (LA) or metastatic breast cancer (MBC).
In April 2018, Clovis Oncology, Inc. received the U.S. Food and Drug Administration approval for Rubraca (rucaparib) tablets, a (PARP) inhibitor indicated for treatment of recurrent ovarian cancer.
Moreover, several key players in the market are focusing on strategic mergers and acquisition strategies for expanding their product portfolios. For instance, in January 2019, GlaxoSmithKline plc, acquired TESARO, Inc. for around US$ 5.1 billion. TESARO, Inc. has developed the approved product Zejula (niraparib), an oral poly ADP ribose polymerase (PARP) inhibitor indicated for ovarian cancer. The acquisition is expected to increase the application of Zejula for multiple cancer treatments.
Major players operating in the global PARP inhibitor market include AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline Plc., Pfizer, Inc., Clovis Oncology Inc., AbbVie Inc., Bristol Myers Squibb, Merck KGaA, Genentech, Inc., Artios Pharma, Repare Therapeutics Inc., Sierra Oncology, Inc., KaryopharmTherapeutics Inc., Ono Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.